Accueil   Diary - News   All news Advanced BioDesign raises additional €9 million from Xerys Funds

Advanced BioDesign raises additional €9 million from Xerys Funds

 

 

Financing will enable company to initiate phase I clinical trial in acute
myeloid leukemia (AML)

 

Lyon, France, February 25, 2020 – Advanced BioDesign, dedicated to developing new therapies for overcoming tumor resistant cancers, announces today that it has raised an additional €9M ($9.8M) financing from Xerys Funds to pursue its clinical development.

 


This is the largest funding raised by Advanced BioDesign following successive fundraising operations since 2013, totalling close to €7.5M ($8.1M). Thanks to Xerys Funds, its longstanding investor, Advanced BioDesign has been able to undertake fundamental work on the mechanism of action for its lead compound ABD-3001 and consolidate knowledge on its anti-cancer properties.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree